Suppr超能文献

HIV-1 感染患者的 CD4+ T 细胞可识别野生型和突变型人类免疫缺陷病毒-1 蛋白酶表位。

CD4+ T cells from HIV-1-infected patients recognize wild-type and mutant human immunodeficiency virus-1 protease epitopes.

机构信息

Division of Clinical Immunology and Allergy, Department of Medicine, School of Medicine Heart Institute (InCor) Institute of Tropical Medicine, University of São Paulo, São Paulo, SP 01246-000, Brazil.

出版信息

Clin Exp Immunol. 2011 Apr;164(1):90-9. doi: 10.1111/j.1365-2249.2011.04319.x. Epub 2011 Feb 24.

Abstract

Human immunodeficiency virus (HIV)-1 protease is a known target of CD8+ T cell responses, but it is the only HIV-1 protein in which no fully characterized HIV-1 protease CD4 epitopes have been identified to date. We investigated the recognition of HIV-1 protease by CD4+ T cells from 75 HIV-1-infected, protease inhibitor (PI)-treated patients, using the 5,6-carboxyfluorescein diacetate succinimidyl ester-based proliferation assay. In order to identify putative promiscuous CD4+ T cell epitopes, we used the TEPITOPE algorithm to scan the sequence of the HXB2 HIV-1 protease. Protease regions 4-23, 45-64 and 73-95 were identified; 32 sequence variants of the mentioned regions, encoding frequent PI-induced mutations and polymorphisms, were also tested. On average, each peptide bound to five of 15 tested common human leucocyte antigen D-related (HLA-DR) molecules. More than 80% of the patients displayed CD4+ as well as CD8+ T cell recognition of at least one of the protease peptides. All 35 peptides were recognized. The response was not associated with particular HLA-DR or -DQ alleles. Our results thus indicate that protease is a frequent target of CD4+ along with CD8+ proliferative T cell responses by the majority of HIV-1-infected patients under PI therapy. The frequent finding of matching CD4(+) and CD8+ T cell responses to the same peptides may indicate that CD4+ T cells provide cognate T cell help for the maintenance of long-living protease-specific functional CD8+ T cells.

摘要

人类免疫缺陷病毒(HIV)-1 蛋白酶是 CD8+T 细胞反应的已知靶点,但它是唯一一种尚未完全鉴定出 HIV-1 蛋白酶 CD4 表位的 HIV-1 蛋白。我们使用 5,6-羧基荧光素二乙酸琥珀酰亚胺酯增殖测定法,研究了来自 75 名接受蛋白酶抑制剂(PI)治疗的 HIV-1 感染者的 CD4+T 细胞对 HIV-1 蛋白酶的识别。为了鉴定可能的广谱 CD4+T 细胞表位,我们使用 TEPITOPE 算法扫描 HXB2 HIV-1 蛋白酶的序列。鉴定出蛋白酶区域 4-23、45-64 和 73-95;还测试了所述区域的 32 个序列变体,编码频繁的 PI 诱导的突变和多态性。平均而言,每种肽与 15 种测试的常见人类白细胞抗原 DR 相关(HLA-DR)分子中的五种结合。超过 80%的患者显示出对至少一种蛋白酶肽的 CD4+和 CD8+T 细胞识别。所有 35 种肽均被识别。该反应与特定的 HLA-DR 或-DQ 等位基因无关。因此,我们的结果表明,在接受 PI 治疗的大多数 HIV-1 感染者中,蛋白酶是 CD4+以及 CD8+增殖性 T 细胞反应的常见靶点。频繁发现与相同肽匹配的 CD4(+)和 CD8+T 细胞反应可能表明 CD4+T 细胞为维持长寿的蛋白酶特异性功能性 CD8+T 细胞提供了同源 T 细胞帮助。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验